Agree that long term Eylea/Fovista should work just as well but if Roche or Novartis buy Ophthotech they can coformulate Fovista&Lucentis and have a unique new product.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.